RBC
AXSM icon

Romano Brothers & Co’s Axsome Therapeutics AXSM Stock Holding History

Romano Brothers & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$1.93K – 352
2022
Q4 		$1.93K Buy
+25
New +$1.49K ﹤0.01% 940

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Romano Brothers & Co's AXSM Position: Q1 2023 in Review

Romano Brothers & Co sold out of Axsome Therapeutics (AXSM) in Q1 2023, closing a stake of 25 shares — an estimated $1.93K sold.

Romano Brothers & Co first reported a position in AXSM in Q4 2022 and held it in 1 quarter. The position peaked at $1.93K in Q4 2022. 197 funds tracked by Wall St. Rank hold AXSM as of Q1 2023.

  • Romano Brothers & Co reported no remaining Axsome Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 25 Axsome Therapeutics shares in Q1 2023, an estimated $1.93K.
  • Romano Brothers & Co first reported a position in Axsome Therapeutics in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Axsome Therapeutics position peaked at $1.93K in Q4 2022.
  • 197 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.